Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial

CLINICAL TRIAL REGISTRATION Clinical Trials.gov NCT00131677.

Pre-exposure Prophylaxis (PrEP)

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).

Annotated Bibliography: Pre-Exposure Prophylaxis

Top Questions in ID: Pre-exposure Prophylaxis for HIV

HIV pre-exposure prophylaxis (PrEP) is highly efficacious at preventing HIV acquisition. This review discusses ways to identify candidates for PrEP, recommended PrEP regimens, baseline and follow-up evaluations, applications of PrEP for HIV-serodiscordant couples, resources to address financial barriers, investigational strategies for PrEP, and educational resources for clinicians and patients.

Pre-exposure and Post-exposure Prophylaxis for Dog Bites

Sir, The recent report on ‘pre-exposure and post-exposure prophylaxis for dog bites’ is very interesting.[1] Bertozzi et al. suggested that ‘monoclonal antibodies represent a promising alternative to traditionally used polyclonal products, and countries with chronic shortages of human rabies immunoglobulin (HRIG) and equine rabies immunoglobulin (ERIG) would benefit greatly from replacement of ...